Clinical trial • Phase III • Oncology
TILT-123 for Melanoma
Phase III trial of TILT-123 for Melanoma. 9 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Melanoma
- Trial Stage
- Phase III
- Drug Modality
- Other|Small molecule|Cell therapy
Key dates
- Initial CTIS Submission Date
- 11-06-2024
- First CTIS Authorization Date
- 05-09-2024
Eligibility
Recruits 9 Vulnerable population not selected; no consent or assent details provided..
- Vulnerable Population
- Vulnerable population not selected; no consent or assent details provided.
Recruitment
- Recruitment Window Months
- 26
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 9
Denmark
- Earliest CTIS Part Ii Submission Date
- 29-08-2024
- Latest Decision Or Authorization Date
- 23-02-2026
- Processing Time Days
- 543
- Number Of Sites
- 1
- Number Of Participants
- 9
Sites
- Site Name
- Region Hovedstaden
- Department Name
- Department of Oncology
- Principal Investigator Name
- Inge Marie Svane
- Principal Investigator Email
- inge.marie.svane@regionh.dk
- Contact Person Name
- Inge Marie Svane
- Contact Person Email
- inge.marie.svane@regionh.dk
- Number Of Participants
- 9
Sponsor
Primary sponsor
- Full Name
- TILT Biotherapeutics Oy
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Finland
Investigational products
- Investigational Product Name
- TILT-123
- Modality
- Other
- Investigational Product Name
- lymphocyte-depleting chemotherapy
- Modality
- Small molecule
- Investigational Product Name
- TILs
- Modality
- Cell therapy
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.